Breaking News

Galapagos, Roche End Fibrosis Alliance

March 8, 2013

Galapagos regains rights to all assays and targets

Galapagos NV and Roche have agreed to end their alliance in fibrosis. Galapagos will receive a payment of $7.5 million for work completed in 2012. Galapagos regains worldwide rights to all fibrosis assays and the targets discovered in the alliance. The company received a total of approximately $20.8 million in upfront and milestone payments from Roche under the collaboration.
"We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, chief executive officer of Galapagos. "Our plan is to find another partner to continue the search for compounds against these debilitating diseases."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent